ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 590,00
-0,94%
Dow Jones
38 952,43
-0,41%
DAX
18 098,98
-0,35%
Brent Oil
84,47
0,34%
Bitcoin
61 799,22
-0,02%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Apogee Therapeutics Inc (APGE)

  7. Apogee Therapeutics Inc (APGE) Actualités

APGE

Apogee Therapeutics (APGE)

Apogee Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:APGE
DateHeureSourceTitreSymboleSociété
08/06/202402h04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:APGEApogee Therapeutics Inc
07/06/202422h02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:APGEApogee Therapeutics Inc
31/05/202402h05Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:APGEApogee Therapeutics Inc
28/05/202413h36Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:APGEApogee Therapeutics Inc
28/05/202413h30GlobeNewswire Inc.Apogee Therapeutics Expands Board of Directors with the Appointment of Lisa Bollinger, MDNASDAQ:APGEApogee Therapeutics Inc
23/05/202413h30GlobeNewswire Inc.Apogee Therapeutics to Participate in Upcoming June Investor ConferencesNASDAQ:APGEApogee Therapeutics Inc
15/05/202422h01GlobeNewswire Inc.Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory DiseasesNASDAQ:APGEApogee Therapeutics Inc
13/05/202413h26Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:APGEApogee Therapeutics Inc
13/05/202413h10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:APGEApogee Therapeutics Inc
13/05/202413h00GlobeNewswire Inc.Apogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial ResultsNASDAQ:APGEApogee Therapeutics Inc
06/05/202414h00GlobeNewswire Inc.Apogee Therapeutics to Participate at the 2024 Bank of America Healthcare ConferenceNASDAQ:APGEApogee Therapeutics Inc
25/03/202412h00GlobeNewswire Inc.Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory DiseasesNASDAQ:APGEApogee Therapeutics Inc
12/03/202421h01GlobeNewswire Inc.Apogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $483 MillionNASDAQ:APGEApogee Therapeutics Inc
11/03/202411h01Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:APGEApogee Therapeutics Inc
08/03/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:APGEApogee Therapeutics Inc
08/03/202400h49GlobeNewswire Inc.Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public OfferingNASDAQ:APGEApogee Therapeutics Inc
08/03/202400h27Edgar (US Regulatory)Form S-1MEF - Registration adding securities to prior Form S-1 registration [Rule 462(b)]NASDAQ:APGEApogee Therapeutics Inc
05/03/202422h23GlobeNewswire Inc.Apogee Therapeutics, Inc. Announces Proposed Underwritten Public OfferingNASDAQ:APGEApogee Therapeutics Inc
05/03/202422h05Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:APGEApogee Therapeutics Inc
05/03/202412h15Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:APGEApogee Therapeutics Inc
05/03/202412h10GlobeNewswire Inc.Apogee Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:APGEApogee Therapeutics Inc
05/03/202412h00GlobeNewswire Inc.Apogee Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases, Exceeding its Trial Objectives Ahead of SchNASDAQ:APGEApogee Therapeutics Inc
04/03/202422h01GlobeNewswire Inc.Apogee to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases on March 5, 2024NASDAQ:APGEApogee Therapeutics Inc
02/01/202413h30GlobeNewswire Inc.Apogee Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:APGEApogee Therapeutics Inc
13/11/202313h30GlobeNewswire Inc.Apogee Highlights Corporate Progress and Reports Third Quarter 2023 Financial ResultsNASDAQ:APGEApogee Therapeutics Inc
30/10/202313h00GlobeNewswire Inc.Apogee Therapeutics to Participate in Upcoming November Investor ConferencesNASDAQ:APGEApogee Therapeutics Inc
27/09/202314h42GlobeNewswire Inc.Apogee Announces Two Abstracts Accepted for Presentation at the 2023 European Academy of Dermatology and Venereology (EADV) CongressNASDAQ:APGEApogee Therapeutics Inc
14/09/202313h30GlobeNewswire Inc.Apogee Therapeutics to Participate at the 2023 Stifel Virtual I&I DayNASDAQ:APGEApogee Therapeutics Inc
29/08/202314h00PR Newswire (US)Paragon Therapeutics Recognizes Key Milestones and Leadership Appointment for First Spinout, Apogee TherapeuticsNASDAQ:APGEApogee Therapeutics Inc
28/08/202313h30GlobeNewswire Inc.Apogee Highlights Corporate Progress and Reports Second Quarter 2023 Financial ResultsNASDAQ:APGEApogee Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:APGE

Dernières Valeurs Consultées

TSX
STC
Sangoma Technologies
ASX
FEMX
Fidelity Global Emerging...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés